サンプル依頼リスト カート
  • English
  • Korean
表紙：小細胞肺がん治療薬の世界市場レポート 2024年
市場調査レポート
商品コード
1415659

小細胞肺がん治療薬の世界市場レポート 2024年

Small Cell Lung Cancer Therapeutics Global Market Report 2024

出版日
ページ情報
英文 175 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
小細胞肺がん治療薬の世界市場レポート 2024年
出版日: 2024年01月24日
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

小細胞肺がん治療薬の市場規模は近年急速に拡大しています。2023年の57億8,000万米ドルから2024年には66億2,000万米ドルに、CAGR14.6％で拡大します。実績期間の成長は、小細胞肺がんの有病率の増加、小細胞肺がんに対する意識の高まり、効果的で便利な治療法に対する需要の高まり、政府の取り組みに起因しています。

小細胞肺がん治療薬市場規模は、今後数年で急成長が見込まれます。2028年の年間平均成長率（CAGR）は13.2％で、108億7,000万米ドルに成長します。予測期間の成長は、小細胞肺がん治療の研究開発活動への投資、トボコ喫煙の増加、化学療法の拡大、ヘルスケア支出の増加に起因します。予測期間における主な動向は、早期発見・スクリーニング法の進歩、臨床試験の拡大、放射線療法の進歩、免疫療法の進歩などです。

肺がんの罹患率の増加は、小細胞肺がん治療薬市場の将来的な拡大の重要な促進要因になると考えられています。肺がんは、肺組織内の異常細胞の無秩序な増殖に起因する咳、胸痛、呼吸困難などの症状を特徴とする悪性疾患です。小細胞肺がんを含む肺がんの治療には、一般的に化学療法、放射線療法、場合によっては標的療法が組み合わされます。例えば、米国に本部を置く政府組織である米国がん協会が2023年1月に報告したところによると、2022年には約23万8340人（男性11万7550人、女性12万790人）の肺がん患者が新たに発生しました。さらに、同年の肺がんによる死亡者数は127,070人（男性67,160人、女性59,910人）と報告されています。したがって、肺がんの有病率の上昇は、小細胞肺がん治療薬市場の成長の原動力となっています。

急増するタバコの使用率は、近い将来、小細胞肺がん（SCLC）治療薬市場の拡大の原動力になると予想されます。タバコの使用増加には、人口増加、マーケティングと広告、不十分な規制、社会的・文化的影響、対処法としてのストレス、ニコチンの中毒性、タバコ製品の入手しやすさなど、いくつかの要因があります。タバコの煙には、多環芳香族炭化水素（PAHs）やニトロソアミンなど、多数の発がん性化合物が含まれています。例えば、カナダの政府機関であるカナダ統計局が報告した2022年7月のたばこの生産量は、2021年6月と比較して5.8％増加しました。さらに、タバコの総販売本数は2022年5月から1.3％増加し、2022年6月には14億本に達しました。さらに2023年5月、米国の政府機関である疾病対策予防センターのデータによると、米国の成人の推定喫煙者数は2830万人で、米国の中高生約308万人が少なくとも1つのたばこ製品を使用しています。憂慮すべきことに、18歳未満の米国青少年約1,600人が、毎日初めてタバコを吸い始めています。その結果、タバコ使用の有病率の上昇は、小細胞肺がん（SCLC）治療薬市場を推進する極めて重要な要因となっています。

2023年の小細胞肺がん治療薬市場では北米が最大地域でした。アジア太平洋は予測期間中に最も急成長する地域となる見込みです。小細胞肺がん治療薬レポートの対象地域は、アジア太平洋、西欧、中東欧、北米、南米、中東およびアフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界の小細胞肺がん治療薬市場、薬剤タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • アテゾリズマブ
  • トポテカン
  • ルルビネクテディン
  • デュルバルマブ
  • メトトレキサート
  • ペンブロリズマブ
  • 世界の小細胞肺がん治療薬市場、治療タイプ別のセグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 化学療法
  • 標的療法
  • その他
  • 世界の小細胞肺がん治療薬市場、投与経路別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 経口
  • 非経口
  • その他
  • 世界の小細胞肺がん治療薬市場、エンドユーザー別のセグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院
  • がん治療センター
  • その他

第7章 地域および国の分析

  • 世界の小細胞肺がん治療薬市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界の小細胞肺がん治療薬市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 小細胞肺がん治療薬市場の競合情勢
  • 小細胞肺がん治療薬市場の企業プロファイル
    • Pfizer Inc.
    • Johnson and Johnson Private Limited
    • F. Hoffmann-La Roche AG
    • AbbVie Inc
    • Bayer AG

第31章 その他の主要および革新的な企業

  • Janssen Pharmaceuticals
  • Novartis AG
  • Merck and Co. Inc.
  • Sanofi S.A
  • Bristol-Myers Squibb Company
  • Astrazeneca plc
  • GSK plc
  • Medtronic plc
  • Eli Lilly and Company
  • Gilead Sciences Inc
  • Boehringer Ingelheim International GmbH
  • Otsuka Pharmaceutical Co. Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Regeneron Pharmaceuticals
  • Mylan N.V.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r12258

“Small Cell Lung Cancer Therapeutics Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on small cell lung cancer therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for small cell lung cancer therapeutics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The small cell lung cancer therapeutics market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Drug Type: Atezolizumab; Topotecan; Lurbinectedin; Durvalumab; Methotrexate; Pembrolizumab
  • 2) By Treatment Type: Chemotherapy; Targeted Therapy; Other Treatment Types
  • 3) By Route Of Administration: Oral; Parenteral; Other Routes Of Administrations
  • 4) By End-Users: Hospitals; Cancer Therapy Centers; Other End-Users
  • Companies Mentioned: Pfizer Inc.; Johnson and Johnson Private Limited; F. Hoffmann-La Roche AG; AbbVie Inc; Bayer AG
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Small-cell lung cancer (SCLC) is a form of lung cancer primarily originating in the bronchi, the air passages of the lungs. Small-cell lung cancer therapeutics encompass a range of medical strategies, treatments, and interventions aimed at the management and treatment of small-cell lung cancer. Typically, a combination of different treatment modalities is employed to achieve the most favorable outcomes.

The primary drugs utilized in small-cell lung cancer therapeutics consist of atezolizumab, topotecan, lurbinectedin, durvalumab, methotrexate, and pembrolizumab. Atezolizumab falls into the category of immunotherapy drugs, specifically an immune checkpoint inhibitor. The treatment approaches encompass chemotherapy, targeted therapy, and various others. These treatments are administered through different routes, including oral, parenteral, and others, with end-users encompassing hospitals, cancer therapy centers, and various other healthcare facilities.

The small cell lung cancer therapeutics market research report is one of a series of new reports from The Business Research Company that provides small cell lung cancer therapeutics market statistics, including small cell lung cancer therapeutics industry global market size, regional shares, competitors with a small cell lung cancer therapeutics market share, detailed small cell lung cancer therapeutics market segments, market trends and opportunities and any further data you may need to thrive in the small cell lung cancer therapeutics industry. This small cell lung cancer therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The small cell lung cancer therapeutics market size has grown rapidly in recent years. It will grow from $5.78 billion in 2023 to $6.62 billion in 2024 at a compound annual growth rate (CAGR) of 14.6%. The growth in the historic period can be attributed to increasing prevalence of small cell lung cancer, growing awareness about small cell lung cancer, growing demand for effective and convenient treatments, government initiatives.

The small cell lung cancer therapeutics market size is expected to see rapid growth in the next few years. It will grow to $10.87 billion in 2028 at a compound annual growth rate (CAGR) of 13.2%. The growth in the forecast period can be attributed to investments in research and development activities for small cell lung cancer treatments, rising toboco smoking, growing chemotherapy, increasing healthcare expenditure. Major trends in the forecast period include advances in early detection and screening methods, clinical trial expansion, advances in radiation therapy, immunotherapy advancements.

The increasing incidence of lung cancer is poised to be a significant driver of the future expansion in the small-cell lung cancer therapeutics market. Lung cancer is a malignant disease characterized by symptoms like coughing, chest pain, and breathing difficulties, resulting from the uncontrolled proliferation of abnormal cells within the lung tissues. The treatment of lung cancer, including small-cell lung cancer, typically encompasses a combination of chemotherapy, radiation therapy, and, in certain cases, targeted therapies. These treatment modalities aim to provide extended survival and an improved quality of life for individuals dealing with lung cancer.For example, in January 2023, as reported by the American Cancer Society, a government organization based in the United States, there were approximately 238,340 new cases of lung cancer (117,550 in men and 120,790 in women) in 2022. Furthermore, there were reportedly 127,070 deaths resulting from lung cancer (67,160 in men and 59,910 in women) during the same year. Hence, the escalating prevalence of lung cancer stands as a driving force behind the growth of the small-cell lung cancer therapeutics market.

The burgeoning prevalence of tobacco use is expected to be a driving force behind the expansion of the small-cell lung cancer (SCLC) therapeutics market in the near future. Several factors contribute to the increased use of tobacco, including population growth, marketing and advertising, insufficient regulation, social and cultural influences, stress as a coping mechanism, the addictive properties of nicotine, and the ready availability of tobacco products. Tobacco smoke contains a multitude of carcinogenic compounds, such as polycyclic aromatic hydrocarbons (PAHs) and nitrosamines. When individuals inhale these substances, they have the potential to damage the DNA within lung cells, causing mutations that can trigger the development of cancer, including SCLC.For instance, in July 2022, as reported by Statistics Canada, a government agency based in Canada, cigarette production witnessed a 5.8% increase compared to June 2021. Additionally, the total number of cigarettes sold rose by 1.3% from May 2022, reaching 1.4 billion in June 2022. Furthermore, in May 2023, data from the Centers for Disease Control and Prevention, a government agency in the United States, indicated that an estimated 28.3 million U.S. adults are cigarette smokers, and approximately 3.08 million U.S. middle and high school students use at least one tobacco product. Alarmingly, around 1,600 U.S. youth under the age of 18 start smoking their first cigarette on a daily basis. Consequently, the rising prevalence of tobacco use serves as a pivotal driver propelling the small-cell lung cancer (SCLC) therapeutics market.

The inadequacy of skilled oncologists is acting as a constraint on the growth of the small-cell lung cancer therapeutics market during the projected period. The scarcity of proficient oncologists poses a significant challenge for individuals dealing with small-cell lung cancer (SCLC). This shortage can result in delayed diagnosis and treatment, an elevated risk of complications, reduced demand for SCLC therapeutics, an increased likelihood of treatment errors, and diminished patient satisfaction.For example, in 2022, as reported by the American Society of Clinical Oncology (ASCO), a professional health organization, there is a projected shortage of 2,393 oncologists anticipated by the year 2025. Consequently, the deficiency of skilled oncologists is impeding the growth of the small-cell lung cancer therapeutics market.

The prominent companies operating in the realm of small-cell lung cancer therapeutics are dedicated to pioneering new drugs as a means to gain a competitive edge and bolster their market position. An illustrative case is that of G1 Therapeutics Inc., a US-based oncology company, which, in February 2021, introduced COSELA (trilaciclib) for small-cell lung cancer therapeutics. This groundbreaking medication received approval from the Food and Drug Administration (FDA), a US-based government agency.COSELA is an injectable solution designed to mitigate the risk of chemotherapy-induced myelosuppression in adult patients undergoing a platinum/etoposide- or topotecan-based regimen for advanced small-cell lung cancer (ES-SCLC). Remarkably, it stands as the first and only medicine developed to safeguard the bone marrow (offering myeloprotection) when administered prior to chemotherapy treatment. This pioneering approach underscores how innovative drug development is transforming the landscape of small-cell lung cancer therapeutics.

In April 2021, Agilent Technologies Inc., a United States-based company renowned for its provision of instruments, software, services, and laboratory consumables, executed the acquisition of Resolution Bioscience. The financial details of this acquisition remain undisclosed. This strategic move by Agilent Technologies is driven by the objective of expanding its capabilities in the realm of next-generation sequencing (NGS)-based cancer diagnostics. It positions the company to leverage state-of-the-art technology, ensuring it is well-prepared to meet the evolving requirements of the rapidly growing precision medicine industry, particularly in the domain of precision oncology solutions.Resolution Bioscience, a United States-based biotechnology firm, specializes in the development of liquid biopsy assays tailored for cancer diagnosis and the monitoring of treatment progress, with a primary focus on small-cell lung cancer.

Major players in the small cell lung cancer therapeutics market are Pfizer Inc., Johnson and Johnson Private Limited, F. Hoffmann-La Roche AG, AbbVie Inc, Bayer AG, Janssen Pharmaceuticals, Novartis AG, Merck and Co. Inc., Sanofi S.A, Bristol-Myers Squibb Company, Astrazeneca plc, GSK plc, Medtronic plc, Eli Lilly and Company, Gilead Sciences Inc, Boehringer Ingelheim International GmbH, Otsuka Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals, Mylan N.V., Astellas Pharma Inc., Daiichi Sankyo Company Ltd., Vertex Pharmaceuticals, Aurobindo Pharma Limited, Kyowa Kirin Co. Ltd.

North America was the largest region in the small cell Lung cancer therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in small cell lung cancer therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the small cell lung cancer therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The small cell lung cancer therapeutics market includes revenues earned by entities by providing diagnosis services, palliative care and radiation therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The small cell lung cancer therapeutics market consists of sales of rova-T, cisplatin and carboplatin. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Small Cell Lung Cancer Therapeutics Market Characteristics

3. Small Cell Lung Cancer Therapeutics Market Trends And Strategies

4. Small Cell Lung Cancer Therapeutics Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Small Cell Lung Cancer Therapeutics Market Size and Growth

  • 5.1. Global Small Cell Lung Cancer Therapeutics Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Small Cell Lung Cancer Therapeutics Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Small Cell Lung Cancer Therapeutics Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Small Cell Lung Cancer Therapeutics Market Segmentation

  • 6.1. Global Small Cell Lung Cancer Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Atezolizumab
  • Topotecan
  • Lurbinectedin
  • Durvalumab
  • Methotrexate
  • Pembrolizumab
  • 6.2. Global Small Cell Lung Cancer Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Chemotherapy
  • Targeted Therapy
  • Other Treatment Types
  • 6.3. Global Small Cell Lung Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Oral
  • Parenteral
  • Other Routes Of Administrations
  • 6.4. Global Small Cell Lung Cancer Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Cancer Therapy Centres
  • Other End-Users

7. Small Cell Lung Cancer Therapeutics Market Regional And Country Analysis

  • 7.1. Global Small Cell Lung Cancer Therapeutics Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Small Cell Lung Cancer Therapeutics Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Small Cell Lung Cancer Therapeutics Market

  • 8.1. Asia-Pacific Small Cell Lung Cancer Therapeutics Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Small Cell Lung Cancer Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Small Cell Lung Cancer Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Small Cell Lung Cancer Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Small Cell Lung Cancer Therapeutics Market

  • 9.1. China Small Cell Lung Cancer Therapeutics Market Overview
  • 9.2. China Small Cell Lung Cancer Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Small Cell Lung Cancer Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Small Cell Lung Cancer Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Small Cell Lung Cancer Therapeutics Market

  • 10.1. India Small Cell Lung Cancer Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Small Cell Lung Cancer Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Small Cell Lung Cancer Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Small Cell Lung Cancer Therapeutics Market

  • 11.1. Japan Small Cell Lung Cancer Therapeutics Market Overview
  • 11.2. Japan Small Cell Lung Cancer Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Small Cell Lung Cancer Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Small Cell Lung Cancer Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Small Cell Lung Cancer Therapeutics Market

  • 12.1. Australia Small Cell Lung Cancer Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Small Cell Lung Cancer Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Small Cell Lung Cancer Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Small Cell Lung Cancer Therapeutics Market

  • 13.1. Indonesia Small Cell Lung Cancer Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Small Cell Lung Cancer Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Small Cell Lung Cancer Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Small Cell Lung Cancer Therapeutics Market

  • 14.1. South Korea Small Cell Lung Cancer Therapeutics Market Overview
  • 14.2. South Korea Small Cell Lung Cancer Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Small Cell Lung Cancer Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Small Cell Lung Cancer Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Small Cell Lung Cancer Therapeutics Market

  • 15.1. Western Europe Small Cell Lung Cancer Therapeutics Market Overview
  • 15.2. Western Europe Small Cell Lung Cancer Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Small Cell Lung Cancer Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Small Cell Lung Cancer Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Small Cell Lung Cancer Therapeutics Market

  • 16.1. UK Small Cell Lung Cancer Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Small Cell Lung Cancer Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Small Cell Lung Cancer Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Small Cell Lung Cancer Therapeutics Market

  • 17.1. Germany Small Cell Lung Cancer Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Small Cell Lung Cancer Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Small Cell Lung Cancer Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Small Cell Lung Cancer Therapeutics Market

  • 18.1. France Small Cell Lung Cancer Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Small Cell Lung Cancer Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Small Cell Lung Cancer Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Small Cell Lung Cancer Therapeutics Market

  • 19.1. Italy Small Cell Lung Cancer Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Small Cell Lung Cancer Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Small Cell Lung Cancer Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Small Cell Lung Cancer Therapeutics Market

  • 20.1. Spain Small Cell Lung Cancer Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Small Cell Lung Cancer Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Small Cell Lung Cancer Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Small Cell Lung Cancer Therapeutics Market

  • 21.1. Eastern Europe Small Cell Lung Cancer Therapeutics Market Overview
  • 21.2. Eastern Europe Small Cell Lung Cancer Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Small Cell Lung Cancer Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Small Cell Lung Cancer Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Small Cell Lung Cancer Therapeutics Market

  • 22.1. Russia Small Cell Lung Cancer Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Small Cell Lung Cancer Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Small Cell Lung Cancer Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Small Cell Lung Cancer Therapeutics Market

  • 23.1. North America Small Cell Lung Cancer Therapeutics Market Overview
  • 23.2. North America Small Cell Lung Cancer Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Small Cell Lung Cancer Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Small Cell Lung Cancer Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Small Cell Lung Cancer Therapeutics Market

  • 24.1. USA Small Cell Lung Cancer Therapeutics Market Overview
  • 24.2. USA Small Cell Lung Cancer Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Small Cell Lung Cancer Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Small Cell Lung Cancer Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Small Cell Lung Cancer Therapeutics Market

  • 25.1. Canada Small Cell Lung Cancer Therapeutics Market Overview
  • 25.2. Canada Small Cell Lung Cancer Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Small Cell Lung Cancer Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Small Cell Lung Cancer Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Small Cell Lung Cancer Therapeutics Market

  • 26.1. South America Small Cell Lung Cancer Therapeutics Market Overview
  • 26.2. South America Small Cell Lung Cancer Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Small Cell Lung Cancer Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Small Cell Lung Cancer Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Small Cell Lung Cancer Therapeutics Market

  • 27.1. Brazil Small Cell Lung Cancer Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Small Cell Lung Cancer Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Small Cell Lung Cancer Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Small Cell Lung Cancer Therapeutics Market

  • 28.1. Middle East Small Cell Lung Cancer Therapeutics Market Overview
  • 28.2. Middle East Small Cell Lung Cancer Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Small Cell Lung Cancer Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Small Cell Lung Cancer Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Small Cell Lung Cancer Therapeutics Market

  • 29.1. Africa Small Cell Lung Cancer Therapeutics Market Overview
  • 29.2. Africa Small Cell Lung Cancer Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Small Cell Lung Cancer Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Small Cell Lung Cancer Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Small Cell Lung Cancer Therapeutics Market Competitive Landscape And Company Profiles

  • 30.1. Small Cell Lung Cancer Therapeutics Market Competitive Landscape
  • 30.2. Small Cell Lung Cancer Therapeutics Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Johnson and Johnson Private Limited
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. F. Hoffmann-La Roche AG
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. AbbVie Inc
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Bayer AG
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Small Cell Lung Cancer Therapeutics Market Other Major And Innovative Companies

  • 31.1. Janssen Pharmaceuticals
  • 31.2. Novartis AG
  • 31.3. Merck and Co. Inc.
  • 31.4. Sanofi S.A
  • 31.5. Bristol-Myers Squibb Company
  • 31.6. Astrazeneca plc
  • 31.7. GSK plc
  • 31.8. Medtronic plc
  • 31.9. Eli Lilly and Company
  • 31.10. Gilead Sciences Inc
  • 31.11. Boehringer Ingelheim International GmbH
  • 31.12. Otsuka Pharmaceutical Co. Ltd.
  • 31.13. Teva Pharmaceutical Industries Ltd.
  • 31.14. Regeneron Pharmaceuticals
  • 31.15. Mylan N.V.

32. Global Small Cell Lung Cancer Therapeutics Market Competitive Benchmarking

33. Global Small Cell Lung Cancer Therapeutics Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Small Cell Lung Cancer Therapeutics Market

35. Small Cell Lung Cancer Therapeutics Market Future Outlook and Potential Analysis

  • 35.1 Small Cell Lung Cancer Therapeutics Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Small Cell Lung Cancer Therapeutics Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Small Cell Lung Cancer Therapeutics Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer